Amgen announced new data for Krystexxa (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment; uncontrolled gout,… read more.
Otsuka Pharmaceutical has filed its antipsychotic agent Rexulti (brexpiprazole) in Japan for a label expansion into agitation associated with dementia due to Alzheimer’s disease. If approved, it would… read more.
For the first time, a panel of spinal cord stimulation (SCS) experts has developed best practices in the nascent field of remote SCS device management . The recommendations… read more.
SeaStar Medical Holding Corporation announces receipt of a correspondence from the FDA Center for Biologics Evaluation and Research (CBER) indicating that the Agency considers the Selective Cytopheretic Device… read more.
LianBio a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced topline results from the Phase III LIBRA clinical trial… read more.
Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK… read more.
Eli Lilly and Company announced that the FDA has approved Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment… read more.
Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as… read more.
Potential to be the first and only self-administered flu vaccine ; AstraZeneca’s Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FluMist… read more.
Eli Lilly and Company announced five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine… read more.
Abbott announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease . Data include findings from the… read more.
Takeda announced that the European Commission (EC) approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
